BiomX (PHGE)

Filed: 24 May 21, 9:15am





Washington, D.C. 20549


Form 8-K



Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 24, 2021


 BiomX Inc. 
 (Exact Name of Registrant as Specified in its Charter) 


Delaware 0001-38762 82-3364020
(State or other jurisdiction
of incorporation)
 (Commission File Number) (I.R.S. Employer
Identification No.)


22 Einstein St., Floor 5
Ness Ziona, Israel
(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code: +972 723942377


 (Former name or former address, if changed since last report) 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on
which registered
Units, each consisting of one share of Common Stock, $0.0001 par value, and one Warrant entitling the holder to receive one half share of Common Stock PHGE.U NYSE American
Shares of Common Stock, $0.0001 par value, included as part of the Units PHGE NYSE American
Warrants included as part of the Units PHGE.WS NYSE American


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☒


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒







Item 2.02 Results of Operations and Financial Condition.


On May 24, 2021, BiomX Inc., or the Company, issued a press release announcing its financial results for the first quarter ended March 31, 2021. A copy of the press release issued in connection with the announcement is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.


Item 7.01 Regulation FD Disclosure.


The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. On May 24, 2021, the Company posted an updated corporate slide presentation in the “Investors” portion of its website at www.biomx.com. A copy of the slide presentation is furnished pursuant to Item 7.01 as Exhibit 99.2 hereto. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits


Exhibit Description
99.1 Press Release dated May 24, 2021
99.2 Investor Presentation dated May 24, 2021







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


May 24, 2021By:/s/ Jonathan Solomon
  Name: Jonathan Solomon
  Title: Chief Executive Officer